SARS-CoV-2 Total and Subgenomic RNA Viral Load in Hospitalized Patients.

BACKGROUND Previous studies demonstrated that SARS-CoV-2 RNA can be detected for weeks after infection. The significance of this finding is unclear and, in most patients, does not represent active infection. Detection of subgenomic RNA has been proposed to represent productive infection and may be a useful marker for monitoring infectivity. METHODS We used RT-qPCR to quantify total and subgenomic nucleocapsid (sgN) and envelope (sgE) transcripts in 185 SARS-CoV-2 positive nasopharyngeal swab samples collected on hospital admission and to relate to symptom duration. RESULTS We find that all transcripts decline at the same rate; however, sgE becomes undetectable before other transcripts. The median duration of symptoms to a negative test is 14 days for sgE and 25 days for sgN. There is a linear decline in subgenomic compared to total RNA suggesting subgenomic transcript copy number is dependent on copy number of total transcripts. The mean difference between total and sgN is 16-fold and the mean difference between total and sgE is 137-fold. This relationship is constant over duration of symptoms allowing prediction of subgenomic copy number from total copy number. CONCLUSIONS Subgenomic RNA may be no more useful in determining infectivity than a copy number threshold determined for total RNA.

[1]  R. Baric,et al.  Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques , 2021, Journal of Virology.

[2]  M. M. van der Eerden,et al.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) , 2021, Nature communications.

[3]  H. Feldmann,et al.  Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys , 2021, Science Translational Medicine.

[4]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[5]  E. Fischer,et al.  Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[6]  C. Wobus,et al.  Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient , 2020, The Journal of Infectious Diseases.

[7]  Malik Peiris,et al.  SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease , 2020, Emerging infectious diseases.

[8]  Eric Song,et al.  Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets , 2020, Nature Microbiology.

[9]  Patricia Harrington,et al.  SARS-CoV-2 detection, viral load and infectivity over the course of an infection , 2020, Journal of Infection.

[10]  S. Alexandersen,et al.  SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication , 2020, Nature Communications.

[11]  Jason Y. Park,et al.  Clinical Validation of a SARS-CoV-2 Real-Time Reverse Transcription PCR Assay Targeting the Nucleocapsid Gene , 2020, The journal of applied laboratory medicine.

[12]  P. V. Van Caeseele,et al.  Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples , 2020, Clinical Infectious Diseases.

[13]  Anne Kimball,et al.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.

[14]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[15]  Hyeshik Chang,et al.  The Architecture of SARS-CoV-2 Transcriptome , 2020, Cell.

[16]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.